Management of Patients with Candidiasis: Overview of New IDSA Guidelines

Abstract

Сandidiasis remains the most frequently occurred form of invasive fungal infections and represents the major part of superficial mycoses. Important factor that contribute to create an accurate guidelines is the increasing number of candidiasis because of the growing immunocompromised population, HIV pandemic, wide application of invasive devices etc. The current guidelines were made by a panel of specialists of the Infectious Diseases Society of America (IDSA) and represent the modified version of 2000 guidelines. Some novel antimycotics (voriconazole, caspofungin, liposomal amphotericin B) and recent general approaches to the treatment of different clinical forms of candidiasis are described. Treatment of patients with systemic and superficial candidiasis, approaches to empiric antifungal therapy, prophylaxis, as well as diagnostic and clinical issues are discussed. For wide range of medical specialists.